Cargando…

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA

Objectives. To compare entecavir (ETV) and tenofovir disoproxil fumarate (TDF) effects in chronic hepatitis B (CHB) patients with high HBV DNA. Method. 96 patients treated initially with tenofovir (TDF group) or entecavir (ETV group) were included in this retrospective study. The following parameter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Hong, Huang, Mingxing, Lin, Guoli, Li, Xiangyong, Wu, Yuankai, Jie, Yusheng, Chong, Yutian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791504/ https://www.ncbi.nlm.nih.gov/pubmed/27034945 http://dx.doi.org/10.1155/2016/6725073

Ejemplares similares

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B
por: Huang, Yi-Jie, et al.
Publicado: (2017)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study
por: Suzuki, Fumitaka, et al.
Publicado: (2021)

Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B
por: Huang, Yi-Jie, et al.
Publicado: (2019)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
por: He, Yi, et al.
Publicado: (2022)

Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels
por: Shi, Hong, et al.
Publicado: (2017)

Seroconversion of Hepatitis B Envelope Antigen (HBeAg) by Entecavir in a Child with Chronic Hepatitis B
por: Hasosah, Mohammed Y., et al.
Publicado: (2012)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

Prevalent HBeAg-negative HBV DNA-positive Chronic Hepatitis B Individuals in Bangladesh
por: Rashed Ul Islam, SM, et al.
Publicado: (2021)

Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection
por: Zhang, Zhanqing, et al.
Publicado: (2021)

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
por: Hadziyannis, Emilia, et al.
Publicado: (2018)

Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials
por: Cai, Dachuan, et al.
Publicado: (2019)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
por: Song, Byung-Cheol, et al.
Publicado: (2014)

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
por: Chen, Ruochan, et al.
Publicado: (2021)

52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
por: Piratvisuth, Teerha, et al.
Publicado: (2013)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir
por: Choi, Youkyung H., et al.
Publicado: (2022)

Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study
por: Liang, Jian, et al.
Publicado: (2013)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

Correlation Between HBsAg Quantitation and HBV DNA in HBeAg-Negative HBV/D Patients
por: Teriaky, Anouar, et al.
Publicado: (2013)

Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
por: Li, Minghui, et al.
Publicado: (2022)

A model to predict liver damage in patients with HBeAg-positive chronic HBV infection
por: Maiocchi, Laura, et al.
Publicado: (2021)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: A community-based study
por: Chen, Ping, et al.
Publicado: (2017)

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
por: Yang, Song, et al.
Publicado: (2016)

Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
por: Svicher, Valentina, et al.
Publicado: (2021)

Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
por: Zeng, Zhan, et al.
Publicado: (2023)

The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease
por: Zhu, Li-Yao, et al.
Publicado: (2016)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
por: Yang, Na, et al.
Publicado: (2021)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B
por: Zhang, Chong, et al.
Publicado: (2020)

Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis
por: Zhang, Zhan-qing, et al.
Publicado: (2019)

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis
por: Zhao, Pan, et al.
Publicado: (2011)

Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
por: Long, Jianfei, et al.
Publicado: (2023)

Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection
por: Song, Aixin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ofpcmj18pfjff8qh7l87lvjnqk